💊 Long-acting buprenorphine in Australia: weekly and monthly depots ✨

Long-acting buprenorphine — the weekly and monthly depot injection forms, marketed in Australia as Buvidal and Sublocade — has quietly changed opioid pharmacotherapy. For a meaningful proportion of people, it eliminates the daily-medication routine entirely, dramatically improves quality of life, and makes treatment retention more achievable. This is a practical guide to what it is, who it suits, and how to get on it.

Why long-acting buprenorphine matters

Daily opioid pharmacotherapy works — that is well-established. But it has costs that are not purely clinical. Daily supervised dosing at a pharmacy can mean a pharmacy visit every morning for months. Daily sublingual buprenorphine requires holding a tablet under the tongue for 5-10 minutes each day. Methadone supervision typically means a pharmacy or clinic queue at a fixed time. For people with jobs, school, families, or rural living, the friction is real, and it is one of the main reasons people drop out of pharmacotherapy.

Long-acting buprenorphine eliminates this. A weekly or monthly injection at a prescriber's clinic delivers steady-state buprenorphine across the entire dosing interval. Between injections, the person takes nothing. They do not need to attend a pharmacy. They do not need to remember a daily medication. They are protected from withdrawal and craving continuously, including overnight and over weekends, which used to be when many lapses happened.

The Australian uptake has been substantial. Long-acting depot buprenorphine is now PBS-funded for opioid dependence, and a growing share of Australian opioid pharmacotherapy patients are now on it.

What the two products are

Two long-acting buprenorphine products are available in Australia.

Buvidal — the weekly and monthly subcutaneous depot. Comes in weekly doses (8mg, 16mg, 24mg, 32mg) and monthly doses (64mg, 96mg, 128mg, 160mg). Injected by a clinician under the skin, usually in the abdomen, buttock, thigh, or back of the upper arm. Forms a small, gel-like depot that releases buprenorphine steadily.

Sublocade — the monthly subcutaneous depot. Comes in 100mg and 300mg monthly doses. Similar mechanism to Buvidal — a depot that releases buprenorphine over a month. The injection site is typically the abdomen.

Both are PBS-listed and require a prescriber authorised to provide opioid pharmacotherapy. The weekly Buvidal option is particularly useful for the early induction phase, where dose adjustment is more frequent.

How induction works

The induction process for long-acting buprenorphine is more involved than starting daily pharmacotherapy, because the depot, once injected, cannot be taken back. Most Australian protocols look like this:

1. The person achieves a period of stability on daily sublingual buprenorphine first — typically several days, sometimes a week or two. This confirms that buprenorphine suits them and at what dose.
2. Dose conversion: an oral dose roughly equivalent to a depot weekly or monthly dose is established.
3. First depot injection is given at the appropriate dose. The person stops daily sublingual buprenorphine that day.
4. Follow-up: review in a few days to a week, dose adjustment if needed (typically using extra weekly Buvidal or supplementary daily sublingual to top up if cravings or withdrawal symptoms emerge).
5. Once stable, the person settles into a weekly or monthly injection routine.

Some prescribers now use a "rapid induction" protocol that goes directly from a brief sublingual stabilisation (sometimes a single dose) straight to depot injection. Both approaches are evidence-supported.

Who long-acting buprenorphine suits

The honest answer is: most people on opioid pharmacotherapy who are clinically stable enough to consider it. The clearer "this is the right tool" indications:

• People with jobs that make daily pharmacy visits hard. Tradies, shift workers, parents, students, people in rural or regional areas.
• People with stable psychosocial functioning who find the daily-medication identity demoralising. The psychological benefit of not taking a medication daily is real.
• People with a history of diversion or injection of sublingual buprenorphine. Depot administration removes the medication from the home entirely.
• People with chaotic daily routines where remembering daily medication is hard. Including some people with significant mental health comorbidities or unstable housing.
• People who travel for work or family. A monthly injection is dramatically easier to plan around than daily supervised dosing.

Where caution is needed

A few situations where daily pharmacotherapy may suit better, at least initially:

• Very early in treatment — the first few weeks of opioid pharmacotherapy involve substantial dose-finding, and daily dosing offers more flexibility.
• Highly unstable use patterns — heavy fentanyl use, rapidly changing tolerance, high-risk relapse patterns. Some clinicians prefer to stabilise on daily methadone first.
• Pregnancy — long-acting buprenorphine in pregnancy is increasingly used in Australia but is a specialist decision, made in consultation with addiction medicine and obstetric services.
• Severe hepatic disease — buprenorphine is processed by the liver, and very high doses sustained over a month are sometimes preferred to be split or avoided.
• Patient preference — some people prefer the routine and the daily-acknowledgement structure of supervised dosing. That is a legitimate clinical preference.

What life on long-acting buprenorphine actually looks like

People who do well on it tend to describe it in similar terms. The first week or two after the first injection takes some adjustment — for most people, the depot delivers steady levels with no perceptible peaks or troughs, which is itself novel after years of daily-dose rhythms. Once stable, a typical month is unremarkable. The injection appointment is the visible piece of treatment; everything else is just life.

Some practical points: no take-home medication means no risk of theft, loss, or accidental ingestion by children or pets. No daily pharmacy queue means no being recognised in a public space as a person on pharmacotherapy. Travel becomes much easier — even international travel, with appropriate documentation. Work commitments, school commitments, parenting all happen in the rhythm of life rather than around the rhythm of medication.

Side effects are similar to daily buprenorphine: occasional injection-site reactions (minor, transient), constipation, sleep changes early on. The depot site itself can be tender for a few days post-injection.

Coming off long-acting buprenorphine

Coming off long-acting buprenorphine is, in some ways, gentler than coming off daily medication — the depot tapers itself naturally as it is absorbed. People deciding to taper typically reduce the depot dose stepwise over months, sometimes transitioning to daily sublingual buprenorphine for the final part of the taper, which allows finer dose adjustment.

The same caveat as with daily pharmacotherapy applies: there is no clinical reason to come off pharmacotherapy before the person is ready. Long-term use is associated with substantially better outcomes — including lower mortality — than premature tapering. For some people, indefinite use is the right answer.

How to access long-acting buprenorphine in Australia

Three main pathways.

Public AOD services. Most state public opioid pharmacotherapy programs now offer Buvidal and/or Sublocade. Access via the state alcohol and drug line or community AOD intake.

Public hospital addiction medicine units. Particularly relevant for people with complex comorbidity, recent hospital presentations, or pregnancy.

Private addiction medicine specialists and accredited GPs. A growing number of GPs are authorised to prescribe long-acting buprenorphine. Private specialist clinics offer shorter wait times and more flexible care. Out-of-pocket costs vary, but the medication itself is PBS-subsidised and the per-script cost is small.

The shift to long-acting buprenorphine is one of the genuinely positive structural changes in Australian addiction medicine over the past decade. If you or someone you care about is on daily opioid pharmacotherapy and finding the daily routine an obstacle to a fuller life, it is a conversation worth having with your prescriber.